NASDAQ:CGEN Compugen (CGEN) Stock Price, News & Analysis $1.44 -0.03 (-1.70%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Compugen Stock (NASDAQ:CGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Compugen alerts:Sign Up Key Stats Today's Range$1.42▼$1.4750-Day Range$1.18▼$1.6252-Week Range$1.13▼$2.66Volume63,336 shsAverage Volume493,158 shsMarket Capitalization$128.95 millionP/E Ratio72.25Dividend YieldN/APrice Target$4.00Consensus RatingBuy Company OverviewCompugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Read More… Compugen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreCGEN MarketRank™: Compugen scored higher than 35% of companies evaluated by MarketBeat, and ranked 727th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCompugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompugen has received no research coverage in the past 90 days.Read more about Compugen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compugen are expected to decrease in the coming year, from ($0.03) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compugen is 71.95, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Compugen is 71.95, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.73.Price to Book Value per Share RatioCompugen has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compugen's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.93% of the outstanding shares of Compugen have been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Compugen has recently decreased by 6.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompugen does not currently pay a dividend.Dividend GrowthCompugen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.93% of the outstanding shares of Compugen have been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Compugen has recently decreased by 6.52%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.23 News SentimentCompugen has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Compugen this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Compugen is held by insiders.Percentage Held by InstitutionsOnly 12.22% of the stock of Compugen is held by institutions.Read more about Compugen's insider trading history. Receive CGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEN Stock News HeadlinesWhat is Leerink Partnrs' Forecast for Compugen Q2 Earnings?May 23 at 1:53 AM | americanbankingnews.comCompugen Ltd. (CGEN) Q1 2025 Earnings Call TranscriptMay 22 at 12:13 AM | seekingalpha.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 23, 2025 | Golden Portfolio (Ad)Compugen First Quarter 2025 Earnings: Misses ExpectationsMay 20 at 1:35 PM | uk.finance.yahoo.comCompugen Ltd. (NASDAQ:CGEN) Q1 2025 Earnings Call TranscriptMay 20 at 9:36 AM | insidermonkey.comCompugen Ltd. (NASDAQ:CGEN) Q1 2025 Earnings Call TranscriptMay 20 at 8:33 AM | msn.comCompugen’s Q1 2025: Clinical Progress and Financial StabilityMay 20 at 12:33 AM | tipranks.comCompugen Ltd.: Compugen Reports First Quarter 2025 ResultsMay 19, 2025 | finanznachrichten.deSee More Headlines CGEN Stock Analysis - Frequently Asked Questions How have CGEN shares performed this year? Compugen's stock was trading at $1.53 at the start of the year. Since then, CGEN shares have decreased by 5.9% and is now trading at $1.44. View the best growth stocks for 2025 here. How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) announced its quarterly earnings results on Monday, May, 19th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.02. The biotechnology company had revenue of $2.28 million for the quarter, compared to analyst estimates of $3.70 million. Compugen had a net margin of 2.67% and a trailing twelve-month return on equity of 2.62%. Read the conference call transcript. Who are Compugen's major shareholders? Compugen's top institutional investors include Taylor Frigon Capital Management LLC (1.18%), ARK Investment Management LLC (1.00%), DAFNA Capital Management LLC (0.31%) and Rothschild Investment LLC (0.21%). How do I buy shares of Compugen? Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXDW), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL) and Company Calendar Last Earnings5/19/2025Today5/23/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGEN CIK1119774 Webwww.cgen.com Phone(723) 765-8585Fax972-3765-8555Employees70Year Founded1993Price Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+172.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E Ratio73.50 Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,750,000.00 Net Margins2.67% Pretax Margin25.27% Return on Equity2.62% Return on Assets1.36% Debt Debt-to-Equity RatioN/A Current Ratio4.14 Quick Ratio4.14 Sales & Book Value Annual Sales$27.86 million Price / Sales4.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book2.01Miscellaneous Outstanding Shares89,237,000Free Float80,759,000Market Cap$131.18 million OptionableOptionable Beta2.61 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CGEN) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.